Pulmonary Aspergillosis;Aspergillus y Pulmón

Archivos de Bronconeumologia

Volumn 40, Issue 3, 2004, Pages 114-122

  Diaz Sanchez C ^a   Lopez Vina A ^b  

^a HOSPITAL DE CABUEÑES   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; IMMUNOMODULATING AGENT; ITRACONAZOLE; VORICONAZOLE;

ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; BRONCHOPULMONARY ASPERGILLOMA; CLINICAL FEATURE; CYSTIC FIBROSIS; HUMAN; LUNG ASPERGILLOSIS; LUNG GRANULOMATOSIS; MORTALITY; NEPHROTOXICITY; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 12144285935     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13057899     Document Type: Review

References (80)

1. McNeil MM, Nash SL, Haijeh RA, Majjeh RA, Phelan MA, Conn LA, et al. Trends in mortality due o invasive mycotic diseases in the United States 1980-1987. Clin Infect Dis 2001;33:641-7.
2. Kaiser L, Huguenin T, Lew PO, Chapis R, Pilter D. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998;77:188-94.
3. Groll AM, Shach PM, Mentzel C, Schneider M. Just, Nuebling J. et al. Trends in the post morten epidemiology of invasive fungal infections et a University hospital. J Infect 1996;33:23-32.
4. Lortholary O, Asloglus S, Moreau P, Herbrecht R, Marimis A, Casassus P, at al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma. A European Organization for Research and Treatment or Cancer Invasive Fungal Infections. Cooperative Group ant the Intergroupe Francais du Myeloma. Clin Infect Dis 2000;30:41-6.
5. Lin SJ, Schranz S, Thentsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001:32:358-66.
6. Marr KA, Bowden RA. Fungal infections in patients undergoing blood ant marrow transplantion. Transpl Infect Dis 1999;1:237-46.
7. Vincent JL, Bihari DJ. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIIC) Study. JAMA 1995;274:639-44.
8. Álvarez Lerma F, Cerda E Jordá R, Palomar M, Bermejo M. Fungal isolates in critically patients admitted to intensive care units. Intensive Care Med 2000;26(Suppl 3):234.
9. Sánchez MA, León C, Nolla J, Jordá R, León MA, Pontes MJ, and Study Group EPCAN. Use of antifungal agents in critically ill patients. A Spanish multicentre study. Final results. Intensive Care Med 2000;26(Suppl 3) 376.
10. Raper KB, Fennell DI. editors. The genus Aspergillus. Huntington: Robert E. Krieger Pub., 1973.
11. Van den Bergh FM, Verweij PE, Voss A. Epidemiology of nosocomial fungal infections: invasive aspegillosis. Diagn Microbiol Infect Dis 1999;34:221-7.
12. Soubani AO, Chandrasekar PK. The clinical spectrum of pulmonary aspergillosis. Chest 2002;121:1988-99.
13. Verweij PE, De Pauw BE. Avances recientes en el manejo de la aspergilosis nosocomial en unidades onco-hematológicas. En: Picazzo JJ, Bouza E, editores. Infección. Bilbao: Servisistem 2000 S.L., 1999; p. 157-76.
14. Ussetti P, De Pablo A, Cruz M. Aspergilosis pulmonar. En: Rello J, Gallego M, editores. Implicaciones terapéuticas de la neumonía nosocomial grave. Barcelona: Edika Med, 2000; p. 97-108.
15. Clancy CJ, Ngujen MH. Acute communite-acquired pneumonia due to Aspergillus in presumably immunocompetens hosts. Chest 1998;114:629-34.
16. Schwartz HJ, Greenberger PA. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 1991;117:138-42.
17. Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A Eurpean epidemiological study. Eur Respir J 2000;16:464-71.
18. Sharma OP, Chwogule R. Many faces of pulmonary aspergillosis. Eur Respir J 1998;12:705-15.
19. Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1998;198:286-91.
20. Rosenberg PA, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977;86:405-14.
21. Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986;56:444-52.
22. Greenberger PA, Miller TP, Roberts M, Smith LL. Allergic Bronchopulmonary aspergillosis in patients with and without bronchiectasis. Ann Allergy 1993;70:333-8.
23. Proceedings of the Cystic Fibrosis Foundation ABPA Consensus Conference; 2001, June 12-13; Bethesda, Md.
24. Rosenberg M, Patterson R, Roberts M, Wang J. The assessment of inmunologic and changes occurring during corticosteroid therapy for allergy bronchopulmonary aspergillosis. Am J Med 1978;64:599-605.
25. Safirstein BH, D'Souza MF, Simon G, Tai EHC, Pepys J. Five-year follow-up of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1973;108:450-9.
26. Wang J, Patterson R, Roberts M. The manegement of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1979;120:87-92.
27. Middleton WG, Paterson IC, Grant IWB, Douglas AC. Asthmatic pulmonary eosinophilia: a review of 65 cases. Br J Dis Chest 1977;71:115-22.
28. British Thoracic Association. Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis: report to the Research Committee of the British Thoracic Association. Br J Dis Chest 1979;73:349-56.
29. Carrie DC, Lueck C, Milburn HB. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax 1990;45:447-50.
30. Crompton GK, Milne LIR. Treatment of bronchopulmonary aspergillosis with clotrimazole. Br J Dis Chest 1973;67:301-7.
31. Shale DJ, Faux JA, Lane DJ. Trial of ketoconazole in non-invasive pulmonary aspergillosis. Thorax 1987;42:26-31.
32. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzano A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-62.
33. Myers J. Bronchocentric granulomatosis. Disease or diagnosis? Chest 1989;96:3-4.
34. Denning DN, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990;12:1147-201.
35. Martínez López MA, Peña JM, Quiralte J, Fernández MC, González JJ, Patrón M. Bronchocentric granulomatosis associated with pure red cell aplasia and lymphadenopathy. Thorax 1992;47:131-3.
36. Reichemberger F, Habicht JM, Gratwohl A, Tamm M. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002;19:743-55.
37. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes: 13 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250-60.
38. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Vallés J. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 1998;26:1473-5.
39. Bulpa PA, Dive AM, Garrino MG, Delos MA, González MR, Ewrard PA, et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 2001;27:59-67.
40. Mehrad B, Paciocco G, Martínez FJ, Ojo TC, Iannettoni MD, Lynch JP III. Spectrum of Aspergillus infection in lung transplant recipients. Case series and review of the literature. Chest 2001;119:169-75.
41. Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS. Review of 342 cases. Chest 1998;114:251-62.
42. Perfect JR, Cox GM, Lee JY, Kauffman CA, De Repentigny L, Chapman SW, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001;33:1824-33.
43. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infection Diseases Society of America. Clin Infect Dis 2000;30:696-709.
44. Brown MJ, Warthy SA, Flint JD. Invasive aspergillosis in the inmunocompromised host: utility of computed tomography and bronchoalveolar lavage. Clin Radiol 1998;53:255-7.
45. Franquet T, Muller NL, Giménez A, Guembe P, De la Torre J, Bague S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics 2001;21:825-37.
46. Kami M, Fukui T, Ogawa S. Use of real-time per on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001;33:1504-12.
47. Maertens J, Verhaegen J, Lagrou K. Screening for circulating galactomannan as a noninvasive diagnosis tool for invasive aspergillosis in prolonged neutropenic patient and stem cell trasplantation recipients: a prospective validation. Blood 2001;97:1604-10.
48. Turín L, Riva F, Galbiati G, Cainelli T. Fast, simple and highly sensitive double-rounded polymerase chain reaction assay to detect medically relevant fungi in dermatological specimens. Eur J Clin Invest 2000;30:511-8.
49. Herbart H, Loffler J, Meisner C. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polimerasa chain reaction screening. J Infect Dis 2000;181:1713-9.
50. Loffler J, Hebart H, Brauchle U, Schumacher U, Einsele H. Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR. J Clin Microbiol 2000;38:3830-3.
51. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Harwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: análisis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96.
52. Tollemar J, Klingspor L, Ringlen O. Liposomal amphotericin B (AmBisome) for fungal infection in immunocompromised aduts and children. Clin Microbiol Infect 2001;7 (Suppl 2):68-79.
53. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. Mycosis Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
54. Stevens DA, Lee JY. Analysis of compassionate use itraconazole for invasive aspergillosis by the NIAID Mycosis Study Group creteria. Arch Intern Med 1997;157:1857-62.
55. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chomic granulomatous disease, o AIDS. Clin Infect Dis 2001;33:E83-E90.
56. Thompson CA. New type of antifungal approved for invasive aspergillosis. Am J Health Syst Pharm 2001;58:558.
57. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JUV, et al. Open randomized of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis. American Society for Microbiology. 41st Interscience Conference on Antimicrobiol Agents and Chemotherapy, Chicago IL, USA, 2001; p. 378.
58. Herbrecht R, Denning DW, Patterson FT, Bennet E, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
59. Pun CH, Boyett JM, Hughes WT, Crist WM. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor after remission induction chemotherapy in children with acute lymphocytic leukemia. N Engl J Med 1997;336:1781-7.
60. Numonaitis J. Use of macrophage colony-atimulating factor in the treatment of fungal infections. Clin Infect Dis 1998;26:1279-81.
61. Rowe JM. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin Infect Dis 1998;26:1290-4.
62. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro H, Arai C, et al. Prophylactic action of oral fluconazole agains fungal infection en neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000;89:1611-25.
63. Schwartz S, Behre G, Heinemann V, Lenz K, Ludwig WD, Wandt H, et al. Aerosolized amphotericin B inhalations as prophylasis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93:3654-61.
64. Singh N. Antifungal prophylaxis for solid sorgan transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000;31:545-53.
65. Patterson JE, Peters J, Calhoon JH, Levine S, Anzueto A, Al-Abdely H, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000;2:22-8.
66. Baughman RP. The lung in the inmunocompromised patient. Infectious complications part 1. Respiration 1999;66:95-100.
67. De Pablo A, Ussetti P, Carreño MC, Lázaro T, Ferreiro MJ, López A, et al. Aspergilosis en el trasplante pulmonar. Enferm Infecc Microbiol Clin 2000;18:209-14.
68. Birsan T, Taghavi S, Klepetko W. Treatment of aspergillus-related ulcerative tracheobronchitis in lung transplant recipients. J Heart Lung Transplant 1998;17:437-8.
69. Hamacher J, Apilioponlos A, Kurt AM. Pre-emptive therapy with azoles in lung transplant patients. Eur Respir J 1999;13:180-6.
70. Kato T, Ikuji U, Hiroki M, Mashiro G, Masayoshi H, Atsushi N, et al. Chonic necrotizing pulmonary aspergillosis in pneumoconiosis. Clinical and radiologic findings in 10 patients. Chest 2002;121:118-27.
71. Franquet T, Muller NL, Giménez A, Domingo P, Plaza V, Bordes R. Semiinvasive pulmonary aspergillosis in chronic obstructive pulmonary disease: radiologic and pathologic findings in nine patients. AJR Am J Roentgenol 2000;174:51-6.
72. Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001;7(Suppl 2):25-31.
73. Pound MW, Drew RH, Perfect JR. Recent andvances in the epidemiology prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis 2002;15:183-194.
74. Kawamura S, Maesaki S, Tomono K, Tashiro T, Kohno S. Clinical evaluation of 61 patient with pulmonary aspergilloma. Intern Med 2000;39:209-12.
75. British Tuberculosis and Thoracic Association. Aspergilloma and residual tuberculous cavities: the results of a resurvey. Tubercle 1970;41:227-45.
76. Yamada H, Kono S, Koga H. Topical treatment of pulmonary aspergilloma and antifungals: relationship between duration of the disease and efficacy of therapy. Chest 1993;103:1421-5.
77. Munk PL, Vellet AD, Rankin RN, Muller NL, Ahmad D. Intracavitary aspergilloma: transthoracic percutaneous injection of amphotericin gelatin solution. Radiology 1993;188:821-3.
78. Rumbak M, Kohler G, Eastrige C, Winer-Muram H, Gravant M. Topical treatment of life-threatening hemoptysis fom aspergilloma. Thorax 1996;51:253-5.
79. Massard G, Roeslin N, Wihlm JM, Dumont P, Witz JP, Morand G. Pleuropulmonary aspergyloma: clinical spectrum and result of surgical treatment. Ann Thorax Surg 1992;54:1159-64.
80. Regnard JF, Icard P, Nicolosi M. Aspergilloma: a series of 89 surgical cases. Ann Thorac Sug 2000;69:898-903.